Agomelatine vs Fluvoxamine

Agomelatine wins for: restoring circadian rhythm and sleep architecture in research models, preserving libido and emotional tone, and avoiding typical SSRI-induced sexual dysfunction or weight gain. Its short half-life and lack of withdrawal also make it attractive for intermittent or on/off protocols.

Fluvoxamine wins for: sigma-1 receptor agonism (neuroprotection, anti-neuroinflammatory protocols), FIASMA activity in post-viral and neuroinflammatory research, strong efficacy in OCD and intrusive-thought models, and documented use at sub-psychiatric doses for research targeting cognition or premature ejaculation. Fluvoxamine's SSRIs effects, though standard, are not its unique selling point in the community.

Pick Agomelatine if:

• The research protocol targets sleep/wake cycle stabilization, especially with circadian disruption or stimulant interference.
• Libido, sexual function, and emotional neutrality are research priorities (avoiding SSRI flattening and sexual side effects).
• Supporting mood and slow-wave sleep post-cycle, on trenbolone, or after stimulant exposure.
• The study mandates a rapid washout or switch with no withdrawal complications.
• Stacking within a protocol using other serotonergic agents or avoiding CYP1A2 inhibitors.

Pick Fluvoxamine if:

• Sigma-1 receptor agonism (neuroprotection, cognitive resilience, or neuroinflammation) is a research goal.
• The protocol models OCD, intrusive thoughts, or premature ejaculation management.
• Low-dose FIASMA effects are required in post-viral fatigue or long-COVID protocols.
• Enhancing BDNF, modulating ER-mitochondria crosstalk, or inhibiting acid sphingomyelinase in CNS-directed research.
• The protocol does not involve compounds heavily dependent on CYP1A2 or CYP2C19 metabolism.